Guggenheim analyst Yatin Suneja downgraded Reata Pharmaceuticals (RETA) to Neutral from Buy with a $172.50 price target after Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RETA:
- Reata Pharmaceuticals downgraded to Neutral from Overweight at Cantor Fitzgerald
- Reata Pharmaceuticals downgraded to Hold from Buy at Stifel
- Biogen Snaps Up Reata Pharma In $7.3B Deal
- Biogen to acquire Reata Pharmaceuticals for $172.50 per share in cash
- Biotech Alert: Searches spiking for these stocks today